UBS raised the firm’s price target on Alignment Healthcare (ALHC) to $21 from $18 and keeps a Neutral rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare: Sustained Membership Growth and Expanding EBITDA Support Buy Rating
- Alignment Healthcare Reports Strong Medicare Advantage Membership Growth
- Alignment Healthcare reports 31% y/y membership growth as of January 1
- Alignment Healthcare price target raised to $30 from $20 at Piper Sandler
- Alignment Healthcare should be bought on recent selloff, says Baird